Publication: Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection
Loading...
Identifiers
Publication date
2020-04-09
Authors
Avellón, Ana ISCIII 
Ala, Aftab
Diaz, Antonio
Domingo, Daniel
Gonzalez, Rosario
Hidalgo, Lorena
Kooner, Paul
Loganathan, Sabarinathan
Martin, Dolores
McPherson, Stuart
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Metrics
Export
Abstract
Hepatitis B virus (HBV) infection is estimated to affect 292 million people worldwide, 90% of them are unaware of their HBV status. The Determine HBsAg 2 (Alere Medical Co, Ltd Chiba Japan [Now Abbott]) is a rapid test that meets European Union (EU) regulatory requirements for Hepatitis B surface antigen 2 (HBsAg) analytical sensitivity, detecting the 0.1 IU/mL World Health Organization (WHO) International HBsAg Standard. This prospective, multicentre study was conducted to establish its clinical performance. 351 evaluable subjects were enrolled, 145 HBsAg-positive. The fingerstick whole blood sensitivity and specificity were 97.2% and 98.5% (15' reading, reference assay cut-off 0.05 IU/mL), sensitivity increasing to 97.9% with the prespecified cut-off 0.13 IU/mL (EU regulations). The venous whole blood, serum and plasma sensitivity was 97.2%, 97.9%, and 98.6%, respectively (15' reading); reaching 99%, 99.5% and 100% specificity. A testing algorithm following up an initial positive fingerstick test result with plasma/serum test demonstrates 100% specificity. The Determine HBsAg 2 test gives 15-minute results with high sensitivity and specificity, making it an ideal tool for point-of-care testing, with the potential to enable large-scale population-wide screening to reach the WHO HBV diagnostic targets. The evaluated test improves the existing methods as most of the reviewed rapid tests do not meet the EU regulatory requirements of sensitivity.
Description
MeSH Terms
DeCS Terms
Bibliographic citation
J Med Virol. 2020;92:3403-3411.